GMAB: Genmab A/S - Summary | Jitta

Genmab A/S

NASDAQ:GMAB

Price
$46.04
Loss Chance
44.8%
5.39JITTA SCORE
17.03%Over Jitta Line
Jitta Ranking
36 / 1,197
660 / 5,063
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (55)
Recent Business Performance (67)
Financial Strength (88)
Return to Shareholders (45)
Competitive Advantage (66)
Jitta Signs
Revenue and EarningConsistent High Growth in the past 5 years
Debt LevelLow Long Term Debt
CapExVery Low
Operating MarginDeclined
Recent Business PerformanceEarning decline 16.32% in the last year
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
5.39
17.03%
1.31
114.85%
2.00
236.83%
Biotechnology
6.10
57.92%
5.54
31.25%
3.95
72.71%
COMPANY DESCRIPTION
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company’s also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.